22157.jpg
Acute Lymphocytic Leukemia (ALL) Pipeline Landscape Report 2024: Comprehensive Insights About 250+ Companies and 250+ Pipeline Drugs
16 avr. 2024 04h59 HE | Research and Markets
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Acute lymphocytic leukemia (ALL) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Acute...
Acute Myeloid Leukemia (AML) Therapeutics Market
Global Acute Myeloid Leukemia (AML) Therapeutics Strategic Research Report 2023: Market to Reach $1.6 Billion by 2030 with Cytarabine Accounting for $571.6 Million
05 déc. 2023 10h48 HE | Research and Markets
Dublin, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Acute...
leukemia-therapeutics-market-share.jpg
Partnerships Drive Innovation in the Leukemia Therapeutics Market: Pfizer Leads with Approval for DAURISMO, Enabling Novel Treatment Possibilities
22 sept. 2023 04h28 HE | Research and Markets
Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and...
22157.jpg
Leukemia Therapeutics Global Market Report 2023: Rises in Product Approvals and Increasing Diagnosis Awareness Drives Growth
02 mai 2023 07h33 HE | Research and Markets
Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Market by Type, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been...
22157.jpg
Global Acute Myeloid Leukemia (AML) Therapeutics Market Report 2022 to 2030: Players Include Abbott Laboratories, Boehringer Ingelheim, Cephalon and Eisai
01 févr. 2023 12h13 HE | Research and Markets
Dublin, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
Global Acute Myeloid Leukemia Therapeutics Market
$1.9 Billion Worldwide Acute Myeloid Leukemia Therapeutics Industry to 2027 - Featuring Abbvie, Amgen, Bristol-Myers Squibb, Celgene and Roche Holding Among Others
17 oct. 2022 04h33 HE | Research and Markets
Dublin, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
22157.jpg
Global Acute Myeloid Leukemia (AML) Therapeutics Market Report 2021: Market to Reach $976.2 Billion by 2026 - Emerging Drug Therapies/Targeted Therapies to Drive Future Growth
06 déc. 2021 03h38 HE | Research and Markets
Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering....
22157.jpg
Acute Myeloid Leukemia (AML) Market Insights & Epidemiology Analysis & Forecasts, 2018-2020 & 2021-2030: Major Markets, Marketed Therapies, Emerging Therapies, Case Reports, Patient Journey
05 août 2021 07h28 HE | Research and Markets
Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML)- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. The...
22157.jpg
Global Acute Myeloid Leukemia (AML) Disease Analysis Report 2021: On Average, it Takes 10.8 Years from Phase I to Approval, Compared to 9.6 Years in the Overall Oncology Space
12 avr. 2021 06h48 HE | Research and Markets
Dublin, April 12, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" report has been added to ResearchAndMarkets.com's offering. AML is a type of heterogeneous...
22157.jpg
Global Acute Myeloid Leukemia (AML) Disease Analysis Report 2020
18 sept. 2020 04h53 HE | Research and Markets
Dublin, Sept. 18, 2020 (GLOBE NEWSWIRE) -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" drug pipelines has been added to ResearchAndMarkets.com's offering. The publisher estimates that in...